Back to search

Peptide record

TPDB01072

Mastoparan B Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Hemolysis Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB01072
Mastoparan B
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb AI4AVP APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
LKLKSIVSWAKKVL
Physicochemical Analysis
C78H137N19O17
RNDCEQGHMFPTY
K
1613.06
11.00
4
0
8
+4
0.35
0.571
160.00
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
5500
340.97
2
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
3
L
4
K
0
M
0
F
0
P
2
S
0
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 3 K: 4 M: 0 F: 0 P: 0 S: 2 T: 0 W: 1 Y: 0 V: 2
Chemical Descriptors
14
C78H137N19O17
1613.06
11.00
+4
0.35
0.571
Free
L
Not Available
Free
Antimicrobial
Hornet,Vespa basalis
Evidence Records 50 records
Evidence 1 Activity

Activity

MIC
Antibacterial
96-128 µg/mL

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml)
Evidence 2 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

S. xylosus

Source & Reference

dbAMP DRAMP

Other

Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/
Evidence 3 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

S. alactolyticus

Source & Reference

dbAMP DRAMP

Other

ainst Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug
Evidence 4 Activity

Activity

MIC
Antibacterial
6 µg/mL

Target

C. koseri

Source & Reference

dbAMP DRAMP

Other

5211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (M
Evidence 5 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

Escherichia coli BL21

Source & Reference

dbAMP DRAMP

Other

S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (
Evidence 6 Activity

Activity

MIC
Antibacterial
3 µg/mL

Target

Escherichia coli JM109 AmpR

Source & Reference

dbAMP DRAMP

Other

alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S
Evidence 7 Activity

Activity

MIC
Antibacterial
128 µg/mL

Target

K.pneumoniae CCRC10694

Source & Reference

dbAMP DRAMP

Other

- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947
Evidence 8 Activity

Activity

MIC
Antibacterial
128 µg/mL

Target

P.aeruginosa

Source & Reference

dbAMP DRAMP

Other

(MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806
Evidence 9 Activity

Activity

MIC
Antibacterial
32-64 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

dbAMP DRAMP

Other

P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806 (MIC 32-64 ug/ml) (for activity data, see AP2890 ref).
Evidence 10 Activity

Activity

Not Available
Anticancer

Target

Colorectal Cancer
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1995

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 11 Activity

Activity

MIC
Antifungal
96-128 µg/mL

Target

S.aureus CCRC12652 or CCRC15211

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml)
Evidence 12 Activity

Activity

MIC
Antifungal
2 µg/mL

Target

S. xylosus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/
Evidence 13 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

S. alactolyticus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ainst Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug
Evidence 14 Activity

Activity

MIC
Antifungal
6 µg/mL

Target

C. koseri

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

5211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (M
Evidence 15 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

Escherichia coli BL21

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (
Evidence 16 Activity

Activity

MIC
Antifungal
3 µg/mL

Target

Escherichia coli JM109 AmpR

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S
Evidence 17 Activity

Activity

MIC
Antifungal
128 µg/mL

Target

K.pneumoniae CCRC10694

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947
Evidence 18 Activity

Activity

MIC
Antifungal
128 µg/mL

Target

P.aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806
Evidence 19 Activity

Activity

MIC
Antifungal
32-64 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806 (MIC 32-64 ug/ml) (for activity data, see AP2890 ref).
Evidence 20 Activity

Activity

MIC
Antiparasitic
96-128 µg/mL

Target

S.aureus CCRC12652 or CCRC15211

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml)
Evidence 21 Activity

Activity

MIC
Antiparasitic
2 µg/mL

Target

S. xylosus

Source & Reference

DRAMP

Other

Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/
Evidence 22 Activity

Activity

MIC
Antiparasitic
32 µg/mL

Target

S. alactolyticus

Source & Reference

DRAMP

Other

ainst Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug
Evidence 23 Activity

Activity

MIC
Antiparasitic
6 µg/mL

Target

C. koseri

Source & Reference

DRAMP

Other

5211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (M
Evidence 24 Activity

Activity

MIC
Antiparasitic
16 µg/mL

Target

Escherichia coli BL21

Source & Reference

DRAMP

Other

S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (
Evidence 25 Activity

Activity

MIC
Antiparasitic
3 µg/mL

Target

Escherichia coli JM109 AmpR

Source & Reference

DRAMP

Other

alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S
Evidence 26 Activity

Activity

MIC
Antiparasitic
128 µg/mL

Target

K.pneumoniae CCRC10694

Source & Reference

DRAMP

Other

- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947
Evidence 27 Activity

Activity

MIC
Antiparasitic
128 µg/mL

Target

P.aeruginosa

Source & Reference

DRAMP

Other

(MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806
Evidence 28 Activity

Activity

MIC
Antiparasitic
32-64 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

DRAMP

Other

P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806 (MIC 32-64 ug/ml) (for activity data, see AP2890 ref).
Evidence 29 Activity

Activity

MIC
Antiviral
96-128 µg/mL

Target

S.aureus CCRC12652 or CCRC15211

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml)
Evidence 30 Activity

Activity

MIC
Antiviral
2 µg/mL

Target

S. xylosus

Source & Reference

DRAMP

Other

Active against Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/
Evidence 31 Activity

Activity

MIC
Antiviral
32 µg/mL

Target

S. alactolyticus

Source & Reference

DRAMP

Other

ainst Gram+ S.aureus CCRC12652 or CCRC15211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug
Evidence 32 Activity

Activity

MIC
Antiviral
6 µg/mL

Target

C. koseri

Source & Reference

DRAMP

Other

5211 (MIC 96-128 ug/ml), S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (M
Evidence 33 Activity

Activity

MIC
Antiviral
16 µg/mL

Target

Escherichia coli BL21

Source & Reference

DRAMP

Other

S. xylosus (MIC 2 ug/ml), S. alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (
Evidence 34 Activity

Activity

MIC
Antiviral
3 µg/mL

Target

Escherichia coli JM109 AmpR

Source & Reference

DRAMP

Other

alactolyticus (MIC 32 ug/ml), Gram- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S
Evidence 35 Activity

Activity

MIC
Antiviral
128 µg/mL

Target

K.pneumoniae CCRC10694

Source & Reference

DRAMP

Other

- C. koseri (MIC 6 ug/ml), E. coli BL21 (MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947
Evidence 36 Activity

Activity

MIC
Antiviral
128 µg/mL

Target

P.aeruginosa

Source & Reference

DRAMP

Other

(MIC 16 ug/ml), E. coli JM109 AmpR (MIC 3 ug/ml), K.pneumoniae CCRC10694 (MIC 128 ug/ml), P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806
Evidence 37 Activity

Activity

MIC
Antiviral
32-64 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

DRAMP

Other

P.aeruginosa (MIC 128 ug/ml), S. Choleraesuis, S. enterica serovar typhimurium CCRC12947, V. parahamelytics CCRC10806 (MIC 32-64 ug/ml) (for activity data, see AP2890 ref).
Evidence 38 Activity

Activity

% Hemolysis
Hemolysis
68.2 27.9 %
[Ref.10667861] 68.2% hemolysis at the peptide concentration of 100 µM is , 27.9% Hemolysis at 50 µM against human red blood cells.

Target

human red blood cells

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
J Pept Res. 2000 Jan 55(1):51-62.##Biopolymers. 1995 Dec 36(6):793-801

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 39 Activity

Activity

38% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
38% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Relationship between the tertiary structures of mastoparan B and its analogs and their lytic activities studied by NMR spectroscopy. | J Pept Res | 2000
Evidence 40 Activity

Activity

68% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
68% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Relationship between the tertiary structures of mastoparan B and its analogs and their lytic activities studied by NMR spectroscopy. | J Pept Res | 2000
Evidence 41 Activity

Activity

41% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
41% Hemolysis | 15 | µM | target cell: Guinea pig erythrocytes

Target

Guinea pig erythrocytes

Source & Reference

NA
DBAASP
Structural requirements for the edema-inducing and hemolytic activities of mastoparan B isolated from the hornet (Vespa basalis) venom. | Toxicon | 1996
Evidence 42 Activity

Activity

81% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
81% Hemolysis | 20 | µM | target cell: Guinea pig erythrocytes

Target

Guinea pig erythrocytes

Source & Reference

NA
DBAASP
Structural requirements for the edema-inducing and hemolytic activities of mastoparan B isolated from the hornet (Vespa basalis) venom. | Toxicon | 1996
Evidence 43 Activity

Activity

96% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
96% Hemolysis | 30 | µM | target cell: Guinea pig erythrocytes

Target

Guinea pig erythrocytes

Source & Reference

NA
DBAASP
Structural requirements for the edema-inducing and hemolytic activities of mastoparan B isolated from the hornet (Vespa basalis) venom. | Toxicon | 1996
Evidence 44 Activity

Activity

5% Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 128 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 45 Activity

Activity

0% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 64 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of short hybrid antimicrobial peptides from pEM-2, mastoparan-VT1, and mastoparan-B. | Chem Biol Drug Des | 2016
Evidence 46 Activity

Activity

50% Cell death
Toxicity
32 µg/mL
Cytotoxic
50% Cell death | 32 | µg/mL | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Design and characterization of short hybrid antimicrobial peptides from pEM-2, mastoparan-VT1, and mastoparan-B. | Chem Biol Drug Des | 2016
Evidence 47 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Goat erythrocytes

Target

Goat erythrocytes

Source & Reference

NA
DBAASP
Enhancing antimicrobial activity of mastoparan-B by amino acid substitution. | J Asia Pac Entomol | 2013
Evidence 48 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Chicken erythrocytes

Target

Chicken erythrocytes

Source & Reference

NA
DBAASP
Enhancing antimicrobial activity of mastoparan-B by amino acid substitution. | J Asia Pac Entomol | 2013
Evidence 49 Activity

Activity

% Hemolysis
Toxicity
68.2 %
Hemolytic
Hemolytic_activity: [Ref.10667861] 68.2% hemolysis at the peptide concentration of 100 µM is , 27.9% Hemolysis at 50 µM against human red blood cells.

Target

erythrocytes

Source & Reference

NA
DRAMP
J Pept Res. 2000 Jan 55(1):51-62.##Biopolymers. 1995 Dec 36(6):793-801
Evidence 50 Hemolysis

Activity

68.2 27.9 %
% Hemolysis
[Ref.10667861] 68.2% hemolysis at the peptide concentration of 100 µM is , 27.9% Hemolysis at 50 µM against human red blood cells.
Hemolysis

Target

human red blood cells

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
J Pept Res. 2000 Jan 55(1):51-62.##Biopolymers. 1995 Dec 36(6):793-801
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.